Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Reversible Inhibitors of Monoamine Oxidase

Known as: Reversible Inhibitor of Monoamine Oxidase 
RIMA shows preference for the A isoenzyme
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Monoamine Oxidase Inhibitors

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Azure B, a metabolite of methylene blue, is a high-potency, reversible inhibitor of monoamine oxidase.
Methylene blue (MB) has been shown to act at multiple cellular and molecular targets and as a result possesses diverse medical… Expand
Is this relevant?
2003
2003
Mapping the Cerebral Monoamine Oxidase Type A: Positron Emission Tomography Characterization of the Reversible Selective Inhibitor [11C]Befloxatone
Befloxatone is a competitive and reversible inhibitor of monoamine oxidase-A (MAOI-A). The aim of the study was to characterize… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
2001
2001
Assessing the comparative effectiveness of antidepressant therapies: a prospective clinical practice study.
BACKGROUND Although efficacy studies suggest equal potency among antidepressant treatments, their effectiveness in clinical… Expand
Is this relevant?
2000
2000
Focal cerebral ischemia-induced escape deficit in rats is ameliorated by a reversible inhibitor of monoamine oxidase-a: implications for a novel animal model of post-stroke depression.
The present investigation was conducted to examine whether a reversible inhibitor of monoamine oxidase (MAO)-A, T-794, affects… Expand
Is this relevant?
Highly Cited
1995
Highly Cited
1995
Long-term antidepressant treatment reduces behavioural deficits in transgenic mice with impaired glucocorticoid receptor function.
Impaired cognitive function and enhanced activity of the hypothalamic-pituitary-adrenocortical system are among the cardinal… Expand
Is this relevant?
1994
1994
Electrophysiologic Evidence for Desensitization of α2-Adrenoceptors on Serotonin Terminals Following Long-Term Treatment with Drugs Increasing Norepinephrine Synaptic Concentration
Previous results from our laboratory have indicated that small intravenous doses of the α2-adrenergic agonist Clonidine increase… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
1993
Review
1993
Brofaromine: a monoamine oxidase-A and serotonin uptake inhibitor.
Brofaromine is a tight-binding, reversible inhibitor of monoamine oxidase-A (MAO-A), with concomitant serotonin (5-HT) uptake… Expand
Is this relevant?
1990
1990
Efficacy of reversible inhibitors of monoamine oxidase-A in various forms of depression.
The design and the main therapeutic results of 3 controlled double-blind studies comparing moclobemide with tricyclics and/or… Expand
Is this relevant?
1990
1990
Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo.
Moclobemide, a new selective and reversible inhibitor of monoamine oxidase A (RIMA), has been compared with various tricyclic… Expand
Is this relevant?
1989
1989
Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
The novel antidepressant moclobemide is a reversible inhibitor of monoamine oxidase (MAO), preferentially of type A. Moclomide… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE